{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"PFS Responders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}],"title":"PFS non-responders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"description":"Number of participants with PFS responders and non-responders at Month 6 was reported. PFS was defined as the time from the date of the first dose of amatuximab to the date of disease progression or death due to any cause, as determined by independent radiologist based on the modified Response Evaluation Criteria in Solid Tumors (RECIST) utilizing the total tumor measurement (performed by computerized tomography (CT)/magnetic resonance imaging (MRI)) which includes the pleural unidimensional measure plus the total of the target lesion(s) measurement. A \"response\", in terms of PFS, was defined to be at least a 6-month stabilization of disease. Progressive disease (PD) as measured by Modified RECIST was defined as an increase of at least 20 percent (%) in the total tumor measurement over the nadir measurement, or the appearance of one or more new lesions.","groups":[{"description":"Participants received amatuximab 5 mg/kg, IV infusion on Days 1 and 8 with pemetrexed 500 mg/m\\^2, IV infusion on Day 1 and cisplatin 75 mg/ m\\^2, IV infusion on Day 1 of each 21-day cycle for approximately 6 cycles during combination therapy. Participants who completed 6 cycles of combination therapy or who discontinued chemotherapy because of intolerable toxicity continued receiving single agent amatuximab 5 mg/kg, IV infusion on Day 1 and 8 of each 21-day cycle until disease progression or death for all subsequent cycles (up to 52 Cycles \\[Cycle length is 21 days\\]).","id":"OG000","title":"All Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Primary Efficacy Population: all participants who received at least 1 dose of amatuximab and met key eligibility criteria (had measurable disease at screening, had unresectable disease, and had at least 1 response assessment or died after starting treatment with amatuximab). Here, number of participants analyzed are first 77 enrolled participants.","reportingStatus":"POSTED","timeFrame":"Month 6","title":"Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6","type":"PRIMARY","unitOfMeasure":"Participants"}